[Skip to Navigation]
Editorial
October 21, 2020

Improving Outcomes for Patients With Epidermal Necrolysis

Author Affiliations
  • 1Perelman School of Medicine, Department of Dermatology, Department of Medicine, University of Pennsylvania, Philadelphia
  • 2Images in Dermatology Editor, JAMA Dermatology
  • 3Department of Dermatology, Brigham and Women’s Hospital, Harvard University of School of Medicine, Boston, Massachusetts
JAMA Dermatol. 2020;156(12):1289-1290. doi:10.1001/jamadermatol.2020.3655

Epidermal necrolysis (EN), encompassing the spectrum of Stevens-Johnson syndrome and toxic EN, is a rare, severe cutaneous drug reaction with an estimated mortality in modern cohorts of 15% to 23%.1-3 The rarity of the disease makes rigorous prospective clinical research difficult, highlighting the need for multicenter, multinational collaborations as well as iterative efforts to validate and build on prior work.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×